An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

Inclusion criteria

• Adult subjects age 18 to 55 years
• Vital signs acceptable at Screening
• Body mass index (BMI) between 18 and 35 kg/m^2 at Screening
• Considered to be in good health, as determined by the Investigator
• Normal ECG findings
• Negative urine screen for drugs of abuse and negative breath test for alcohol
• Negative hepatitis B surface antigen, hepatitis C antibody, and HIV1 and HIV2 antibody tests within the last 28 days
• Ability to provide written informed consent

Exclusion criteria

• Use of any medication (including acetaminophen) within 5 days of dosing
• Use of any investigational agent or selective serotonin reuptake inhibitors (SSRIs) within 30 days of study start
• Administration of any protein or antibodies within 90 days of study start
• Donation or loss of greater than 450 mL of blood within 45 days of study start
• Known history of hepatic disease or significantly abnormal liver function tests
• History of alcoholism or substance abuse within 3 years prior to study start
• Participation in any other clinical study within 30 days preceding the first dose of study drug
• Positive serum pregnancy test